HOME
SERVICES
INDUSTRIES
PROFESSIONALS
CLIENTS
Clients
Large Volume Filers
Small Medium Enterprises
Global
Brand Leaders
STARTUP
BLOG
ABOUT
About Us
PCK Patents
Practice Overview
Recognition
Careers
Diversity
Pro Bono Services
PCK Events
CONTACT
MyPCK
Hearsay
Filter by
Categories
Tags
Show all
Article
Confusion
Contract
Copyright
Corporate
Domain Names
Employment
Expungement
Expungement
Grey Marketing
Industrial Designs
Licensing
Obviousness
Opposition
Passing Off
Patent
Patent Infringement
Patent Strategy
PM(NOC)
Procedure
Prosecution
recognition
Services
Summary
Trade Secrets
Trade-mark
Use
Validity
35 US Code §101
3D printing
Abandonment
abstract theorems
Abuse of Process
Accounting of Profits
acquired distinctiveness
actions
actual notice
agreement
Alice/Mayo Test
Ambiguity
Amendments
Anticipation
Appeal
Apple
application
application fee
arbitrary
arbitration
Artificial Intelligence
Assignment
Australia
Bad Faith
Bargain Theory
Bill C-31
Bill C-43
Bill C-8
Bill C-86
Biologics
biosimilar
Biotech Patents
Blockchain
border measures
Brand
broadcasting
budget
burden of proof
business
CAFC
Canada
Canada Gazette
Cannabis Law
causal link
cdrp
CEEO
Certificate of Supplementary Protection
champerty
Chemical Patent
chemistry
ciba
CIPO
CIPO errors
CIRA
Claim Construction
Class Actions
clerical error
collateral estoppel
College of Patent Agents and Trademark Agents
combination drugs
commissioner
Common General Knowledge
Complete Code
Confidential Information
confidentiality
confidentiality order
Conflict of Interest
Confusion
Constitution
consumer goods
contract
contributory infringement
Copyright
Copyright Infringement
copyright test
corrections
Costs
counterfeit
Court of Appeals for the Federal Circuit
COVID-19
CSP
cybersecurity
Damages
Data
Data Protection
deadline
defamation
defences
Delay to Market Entry
descriptive
Design Patents
deviation
digital infringement
disclosure
Discovery
Distinctiveness
Diversity
division of powers
divisionals
DNA Patents
domain names
dominant feature
Dosage Range
Double Patenting
doubtful cases
Due Care
Duty of Candor
E-Commerce
Early dismissal
economics
Employment
errors
essentiality of elements
Ethics
Europe
Events
Evidence
examination quality
examination statistics
Examiner
Expedited Examination
Expert Blinding
Expert Evidence
expiry
Expungement
extraterritoriality
Fair Use
federal circuit
Federal Court
Federal Court of Appeal
fees
file wrapper
Filing
filing date
filing fee
financial services
Food and Drug Regulations
Foreign Filing License
foreign issue estoppel
forum selection
fraud
Free World Trust
frivolous
funding
future infringement
generics
geographical indications
Good Faith
goods
Google
Government
Grace Period
grey marketing
Hague
Hatch-Waxman
Health Canada
Hearsay
Honest Contractual Performance
ICSID
Illegality
Improver
Indefiniteness
Inducement
Industrial Designs
inherent distinctiveness
Injunction
Injunctions
Innovation
Innovative Drugs
Insufficient Disclosure
Intellectual Property
intent
Inter Partes Review
interlocutory injunction
Internet
Internship
intra vires
Investors
IP Lawyer
IP Strategy
IPIC
IPO
ISP
IT patent
ITC
Jurisdiction
Late fee
Legal Retainer
legal test
Legislative Reform
Liability
Licensing
life science
limitation periods
Litigation
litigation funding agreement
Madrid Protocol
Maintenance Fee
Marking Requirement
materiality
medical
method
Methods of Medical Treatment
misleading
motion
Motion to dismiss
Motion to strike
NAFTA
national phase entry
Natural Health Product
new evidence
Non-Infringing Alternative
Non-Practicing Entity
notice of allegation
notice to rectify
Novelty
obivous error
Obviousness
Official Marks
On-Sale Bar
ontario
Overbreadth
Ownership & Inventorship
Passing Off
Patent Act
Patent Agents
Patent Appeal Board
Patent Application
Patent Drafting
Patent Infringement
Patent Litigation
Patent Office
patent office errors
patent practicioner
patent prosecution
patent requirement
Patent Rules
Patent Strategy
Patent Term Adjustment
Patent Textbook
Patent Trial and Appeal Board
Patent Trolls
patentability
Patentable Subject Matter
Patents
PCT
Pharmaceutical Patent
Pharmaceutical Pricing
PLT
PM(NOC)
PM(NOC) Damages
PMPRB
POSITA
pride
prior art
Prior Disclosure
prior use
Priority
Privilege
procedure
Product Specificity
prohibited marks
Promise Doctrine
proprietor
Prosecution
Prosecution History
protective order
prothonotaries
Provisional Patent
public sale
Public Servant
Punitive Damages
Recognition
Records
registration
Reinstatement
Reissue
Remedies
representation
request for correction
requisition
responding
review
risk
Royalties
s. 27
s. 45
s. 53
sale
Scheduling
Scholarship
SCOTUS
second person
Secondary Infringement
secondary meaning
secret sale
section 28
Section 45
section 50
Section 52
section 56
section 7
security
Selection Patents
Services
settlement
Site-Blocking Orders
skilled person
Software
Software Copyright
Software Patent
Sound Prediction
Specification
sponsorship
Springboard Profits
SRED
Standard of Proof
Standard of Review
Standard-Essential Patents
standing
standing to appeal
Start-up
Startups
Statute of Monopolies
stay
Strategy
Sufficiency
Summary Judgment
superior court
Supreme Court of Canada
surname
Technology
Telecommunications
time frame
TPP
Trade Secrets
Trade-Mark
Trademark
Trademark Infringement
Trademark Licensing
Trademark Opposition
Trademark Trial and Appeal Board
Trademarks Act
treaty
UK
United Kingdom
United States
Use
useful article
USMCA
USPTO
Utility
Validity
Variant
Varying records
Velocity
vexatious
who's who legal
Written Description
admin
administrator
Caroline Henrie
Damian Rolfe
Gillian Burrell
PCK
PCK-Reporter
pckip
Monica
Wendy Low
August 22, 2017
August 22, 2017
Federal Court of Appeal remits decision based on hearsay evidence back to the Federal Court for redetermination
2016 FCA 161 - The FCA remitted a proceeding back to the FC for redetermination after agreeing with Pfizer that part of Teva’s evidence in the FC decision was based on hearsay.
